125 related articles for article (PubMed ID: 34102775)
1. Initial Ca 125 Value as a Predictive Marker for High-grade Serous Ovarian Cancer.
Ay S; Ozyukseler DT; Dulgar O; Basak M; Yildirim ME; Gumus M
J Coll Physicians Surg Pak; 2021 Jun; 31(6):651-656. PubMed ID: 34102775
[TBL] [Abstract][Full Text] [Related]
2. Impact of lymph node ratio on survival in stage III ovarian high-grade serous cancer: a Turkish Gynecologic Oncology Group study.
Ayhan A; Ozkan NT; Sarı ME; Celik H; Dede M; Akbayır Ö; Güngördük K; Şahin H; Haberal A; Güngör T; Arvas M; Meydanlı MM
J Gynecol Oncol; 2018 Jan; 29(1):e12. PubMed ID: 29185270
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA125.
AlSomairi A; Himayda S; Altelmesani A; Lee YJ; Lee JY
Gynecol Oncol; 2024 Feb; 181():155-161. PubMed ID: 38176127
[TBL] [Abstract][Full Text] [Related]
4. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
[TBL] [Abstract][Full Text] [Related]
5. A 2-Protein Signature Predicting Clinical Outcome in High-Grade Serous Ovarian Cancer.
Jin C; Xue Y; Li Y; Bu H; Yu H; Zhang T; Zhang Z; Yan S; Lu N; Kong B
Int J Gynecol Cancer; 2018 Jan; 28(1):51-58. PubMed ID: 28976449
[TBL] [Abstract][Full Text] [Related]
6. Comparison of clinical behavior between mucinous ovarian carcinoma with infiltrative and expansile invasion and high-grade serous ovarian carcinoma: a retrospective analysis.
Hada T; Miyamoto M; Ishibashi H; Matsuura H; Kakimoto S; Iwahashi H; Tsuda H; Takano M
Diagn Pathol; 2022 Jan; 17(1):12. PubMed ID: 35057833
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and predictive relevance of CA-125 at primary surgery of ovarian cancer.
Mury D; Woelber L; Jung S; Eulenburg C; Choschzick M; Witzel I; Schwarz J; Jaenicke F; Mahner S
J Cancer Res Clin Oncol; 2011 Jul; 137(7):1131-7. PubMed ID: 21344262
[TBL] [Abstract][Full Text] [Related]
8. Expression of serum human epididymal secretory protein E4 at low grade and high grade serous carcinomas.
Zhu YF; He LS; Zhang ZD; Huang QS
Asian Pac J Trop Med; 2012 Dec; 5(12):925-30. PubMed ID: 23199707
[TBL] [Abstract][Full Text] [Related]
9. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
10. High-grade ovarian serous carcinomas: Significant correlation of histologic patterns with IMP3 and E-Cadherin predicting disease recurrence and survival.
Mohanty SK; Tiwari A; Singh C; Walsh C; Chuang F; Kim E; Singh K; Dadmanesh F
Ann Diagn Pathol; 2019 Jun; 40():30-39. PubMed ID: 30921622
[TBL] [Abstract][Full Text] [Related]
11. Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients.
Feng Z; Wen H; Bi R; Duan Y; Yang W; Wu X
BMC Cancer; 2016 Jan; 16():43. PubMed ID: 26817451
[TBL] [Abstract][Full Text] [Related]
12. The prognostic value of nuclear morphometric analysis in serous ovarian carcinoma.
Palmer JE; Sant Cassia LJ; Irwin CJ; Morris AG; Rollason TP
Int J Gynecol Cancer; 2008; 18(4):692-701. PubMed ID: 17944918
[TBL] [Abstract][Full Text] [Related]
13. Long term follow-up of a large series of stage-II/III atypical proliferative serous ovarian tumors.
Maria S; Faron M; Maulard A; Pautier P; Leary A; Chargari C; Genestie C; Gouy S; Morice P
Gynecol Oncol; 2020 Sep; 158(3):659-665. PubMed ID: 32571680
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer.
Paik ES; Kim JH; Kim TJ; Lee JW; Kim BG; Bae DS; Choi CH
J Gynecol Oncol; 2018 Jan; 29(1):e13. PubMed ID: 29185271
[TBL] [Abstract][Full Text] [Related]
15. Combined prognostic importance of CA 125, histopathologic grade and DNA-index in advanced ovarian cancer.
Nyvang GB; Mogensen O; Bichel P; Jakobsen A
Eur J Gynaecol Oncol; 2000; 21(6):569-72. PubMed ID: 11214611
[TBL] [Abstract][Full Text] [Related]
16. Can CA-125 predict lymph node metastasis in epithelial ovarian cancers in Turkish population?
Sudolmuş S; Köroğlu N; Yıldırım G; Ülker V; Gülkılık A; Dansuk R
Dis Markers; 2014; 2014():492537. PubMed ID: 24795494
[TBL] [Abstract][Full Text] [Related]
17. High grade, advanced, serous ovarian cancer with low serum CA125 levels.
Asali A; Haj-Yehia N; Zehavi T; Perry T; Beiner M; Fishman A; Kadan Y
J Obstet Gynaecol; 2021 Oct; 41(7):1107-1111. PubMed ID: 33427544
[TBL] [Abstract][Full Text] [Related]
18. External validation of a 'response score' after neoadjuvant chemotherapy in patients with high-grade serous ovarian carcinoma with complete clinical response.
Zorzato PC; Zannoni GF; Tudisco R; Pasciuto T; Di Giorgio A; Franchi M; Scambia G; Fagotti A
Int J Gynecol Cancer; 2020 Jan; 30(1):67-73. PubMed ID: 31754067
[TBL] [Abstract][Full Text] [Related]
19. Small Foci of Serous Component as a Predictor of Recurrence and Prognosis for Stage IA Endometrial Carcinomas.
Miyamoto M; Takano M; Tsuda H; Soyama H; Aoyama T; Ishibashi H; Kato K; Iwahashi H; Matuura H; Yoshikawa T; Suzuki A; Hirata J; Furuya K
Oncology; 2017; 93(1):29-35. PubMed ID: 28259868
[TBL] [Abstract][Full Text] [Related]
20. CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer.
Chen X; Zhang J; Cheng W; Chang DY; Huang J; Wang X; Jia L; Rosen DG; Zhang W; Yang D; Gershenson DM; Sood AK; Bast RC; Liu J
Int J Gynecol Cancer; 2013 Jun; 23(5):815-22. PubMed ID: 23669443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]